Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells $677,379.59 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 11,269 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $677,379.59. Following the completion of the sale, the chief executive officer directly owned 14,731 shares of the company’s stock, valued at approximately $885,480.41. The trade was a 43.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ian Mortimer also recently made the following trade(s):

• On Friday, March 13th, Ian Mortimer sold 7,308 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $55.23, for a total transaction of $403,620.84.
• On Monday, March 9th, Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00.
• On Friday, January 2nd, Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00.

Xenon Pharmaceuticals Stock Down 4.6%

XENE opened at $55.23 on Friday. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95. The company has a 50-day moving average price of $43.71 and a 200 day moving average price of $41.92. The company has a market cap of $4.59 billion, a PE ratio of -12.67 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the prior year, the business posted ($0.84) earnings per share. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday. Deutsche Bank Aktiengesellschaft boosted their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday. Robert W. Baird upped their price target on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Guggenheim reaffirmed a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $71.94.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new position in Xenon Pharmaceuticals during the second quarter worth about $32,000. Danske Bank A S acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at about $32,000. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $33,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.